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Abstract
We studied a 32-yr-old man with a benign paraproteinemia (IgA)
affected by severe nonfamilial hypercholesterolemia. In vitro ex-
periments demonstrated that lipoprotein-deficient serum (LPDS)
from the patient inhibited the binding of low density lipoprotein
(LDL) to human skin fibroblasts cultured in vitro (up to 70%)
whereas LPDS from controls had no effect. Removal of IgA
from the patient's serum by immunoprecipitation with mono-
specific antisera abolished the inhibition of LDL binding. IgA
isolated from the serum of the patient by affinity chromatography
inhibited, in a dose-dependent manner, the binding of LDL to
human skin fibroblasts in vitro, thus showing an IgA-mediated
effect.
Ligand-blotting experiments demonstrated that the para-
protein directly interacts with the LDL receptor, thus inhibiting
the binding of the lipoprotein. Treatment of the receptor protein
with reducing agents blocked the interaction of the antibody with
the LDL receptor. From these data we speculate that this au-
toantibody may be responsible for the severe nonfamilial hy-
percholesterolemia of the patient.
Introduction
Familial type Iha hypercholesterolemia is characterized by high
levels ofplasma cholesterol and premature coronary heart disease
(1). Brown, Goldstein, and their co-workers in a series ofelegant
studies have elucidated the molecular basis of this syndrome,
i.e., partial or almost complete lack of low density lipoprotein
(LDL) receptors (2). The clinical counterpart of this biochemical
defect is the presence of xanthomata, with typical distribution,
and early coronary and aortic atherosclerosis which eventually
leads to myocardial infarction.
Type Ila phenotype, however, may also result from a number
of secondary causes. Hypothyroidism, for instance, induces hy-
percholesterolemia due to a down-regulation ofLDL receptors,
which can be reversed by specific treatment (3). The concept of
autoimmune hyperlipoproteinemia was proposed by Beaumont
and Beaumont (4), and since then patients with hyperlipemia
have been found who have autoantibodies to circulating lipo-
proteins (5-7) as well as to enzymes related to lipoprotein ca-
tabolism (8). So far no patient has been reported to have auto-
antibodies to the LDL receptor. In this article we report on a
subject affected by severe nonfamilial hypercholesterolemia
whose serum contains a paraprotein that binds to the LDL re-
ceptor, thus inhibiting the ligand-receptor interaction.
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Case report. F.F., a 31-yr-old man, with a 10-yr history of
hypercholesterolemia, was referred to us in January 1984 because
of hypercholesterolemia (typically in the range of 600-900 mg/
dl). The patient had xanthoma at the elbows and thickening of
achilles tendon was observed.
Known secondary causes of hypercholesterolemia were ex-
cluded. The familial anamnesis was negative and biochemical
analysis indicated that his relatives were normocholesterolemic,
suggesting a nonfamilial type hIa hypercholesterolemia. All rel-
evant laboratory tests gave normal findings with the exception
of immunoelectrophoresis of the serum proteins which showed
the presence of a spike in the ,B-globulin zone. This peak was
identified as an IgA (K-chain) by use of commercially available
antibodies. IgA, IgG, and IgM plasma concentrations were within
the normal range.
Bone marrow plasma cell count was normal (<5%) as well
as the radionuclide bone scan and the complete skeletal x-ray
analysis. Bence-Jones proteins were absent from the urine. These
findings suggested the diagnosis of a monoclonal gammopathy
of undetermined significance (9). The patient had angina and
had had a myocardial infarction; he was also hypertensive (190/
100 mmHg) for which he was treated with j3-biockers. At age of
31 he suddenly died at home during the night. An autopsy was
not performed.
Methods
Materials. Eagle's minimum essential medium (F- 1), fetal calf serum,
trypsin-EDTA (X 1), penicillin (10,000 U/ml), streptomycin (10 mg/
ml), tricine buffer (1 M, pH 7.4), Hepes (1 M, pH 7.4) and nonessential
aminoacids (X 100), were purchased from Gibco (Grand Island, NY);
disposable culture flasks and petri dishes were from Corning Glass Works
(Corning, NY), filters from Millipore Corp. (Bedford, MA). Sodium 1251
iodide, carrier free in 0.1 N NaOH was purchased from Amersham
(Amersham, United Kingdom).
Sephadex G-25 and Sepharose 4B activated with cyanogen bromide
(CNBr) were obtained from Pharmacia (Uppsala, Sweden). Kits for en-
zymatic determination of plasma lipids were from Boehringer (Mann-
heim, Federal Republic of Germany). Monospecific antisera to IgA and
immunodiffusion plates for IgA and IgG were gifts from Dr. Porta (Behr-
ing, Scoppito, Italy). Nitrocellulose membranes and all electrophoresis
material and equipment were purchased from Bio-Rad Laboratories
(Richmond, CA). All the reagents were analytical grade.
Plasma lipids and lipoproteins. Plasma was obtained in EDTA (0.1%),
cholesterol and triglycerides were determined by enzymatic procedures,
apolipoproteins (apo)' B and A-I were determined by radial immuno-
diffusion using antibodies raised in our laboratory in rabbits against pu-
rified apo B and apo A-I. Lipoproteins were fractionated by ultracentri-
fugation (10) using the following density cuts: very low density lipoprotein
(VLDL)-d < 1.006 g/mI, LDL-d < 1.019-1.063 g/mI, high density
lipoprotein subfraction 3 (HDL3)-d < 1.125-1.21 g/mI. Fractions were
spun for 16, 24, and 48 h respectively at 40,000 rpm in a Beckman 50.2
1. Abbreviations used in this paper: apo, apolipoprotein; LPDS, lipopro-
tein-deficient serum.
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Ti Rotor (Beckman Instruments, Inc., Palo Alto, CA) at 12'C. Lipo-
protein triglyceride and cholesterol content was determined by enzymatic
procedures. Lipoprotein-deficient serum (LPDS) was obtained as the
serum fraction at d< 1.25 g/ml, by ultracentrifugation for 72 h at 40,000
rpm at 12'C in a Beckman 60 Ti Rotor. Densities were adjusted by
addition of solid KBr to the solutions.
All lipoproteins and the LPDS were dialyzed extensively against NaCl
0.15 M, EDTA 0.3 mM, pH 7.4, and stored at 4VC after sterilization
through a Millipore 0.45-Mm filter. The LPDS was stored at -20'C and
thawed just before use. HDL3 were further purified by heparin-Sepharose
affinity chromatography to remove apo B- and apo E-containing lipo-
proteins (1 1).
Lipoproteins (LDL and HDL) were labeled with 125I according to
Bilheimer et al. (12). Specific activities were 150-230 cpm/ng protein
for LDL and 150 cpm/ng protein for HDL3. Free 1251I was removed by
column chromatography on a Sephadex G-25 column eluted with 0.15
M NaCi, 0.3 mM EDTA, pH 7.4. Fractions containing lipoproteins were
collected and dialyzed against 0.15 M NaCl, 0.3 mM EDTA, pH 7.4,
overnight at 4°C. Free iodine accounted for <1% of total radioactivity.
Lipid-associated radioactivity was always <5% for LDL and 4% for HDL.
Immunoglobulin purification. The d < 1.25 g/ml plasma fraction
(LPDS) was used to study the effect ofthe patient's serum on lipoprotein
metabolism. In some experiments IgA was immunoprecipitated using
monospecific antisera at 4°C for 24 h and the supernatant was collected
after centrifugation for 20 min at room temperature. The effectiveness
of the precipitation was evaluated by radial immunodiffusion.
IgA was purified from control and the patient's LPDS by affinity
chromatography using a rabbit anti-human IgA immunoglobulin coupled
to a Sepharose 4B activated with CNBr as recommended by the producers.
The LPDS was loaded onto the column (2.6 X 4 cm) and eluted with
phosphate buffer, pH 7.4 (10 vol of the column) followed by 10 vol of
glycine buffer (1 M, pH 2.5). Fractions of 0.5 ml were collected and
immediately adjusted to pH 7-7.4 with 1 M NaOH. Protein content was
measured as described by Lowry et al. (13). IgA was >95% pure as de-
termined by radial immunodiffusion using commercially available plates.
The interaction of LPDS (from control and patient F.F.'s serum)
with LDL was also determined by affinity chromatography using a LDL-
Sepharose column prepared using Sepharose 4B activated with CNBr as
described by the producers. The LPDS was loaded onto the column (2.6
X 3 cm) and eluted first with phosphate-buffered saline (PBS) (10 vol of
the column) and then with glycine buffer (I M, pH 2.5). Fractions of
0.25 ml were collected and immediately adjusted to pH 7-7.4 with 0.1
M NaOH and their protein content was determined according to Lowry
et al. (13). The column was used within 2 d after its preparation.
Cell culture. Human skin fibroblasts were grown from explants of
skin biopsies obtained from the patient and from normolipidemic clin-
ically healthy individuals. Cells were grown in monolayers and maintained
in 75-cm2 plastic flasks at 37°C in a humidified atmosphere of95% air,
5% CO2 in F- 1 medium supplemented with 10% fetal calf serum, non-
essential aminoacid solution (1%, vol/vol), penicillin (100 U/ml), strep-
tomycin (100 gg/ml), tricine buffer (20 mM, pH 7.4), and NaCO3
(24 mM). For all experiments, cells from the stock flask were dissociated
with 0.05% trypsin-0.02% EDTA at confluency (5-15 passages), seeded
in 60-mm plastic petri dishes (2.5 X 10' cells), and used just before
reaching confluency, usually 6 d after plating. The medium was changed
every 2-3 d. Cell viability, assessed by Trypan blue exclusion, was
always >95%.
The cell surface binding of 1251I-LDL was determined as heparin-
releasable radioactivity (14). Monolayers were then digested in 0.1 N
NaOH at room temperature overnight; one aliquot was counted for re-
sidual cell radioactivity as a measure ofLDL internalization and another
aliquot used for cell protein assay (13). For total uptake (binding and
internalization) of LDL, cell monolayers were directly digested in 0.1 N
NaOH after standard washing procedures. The specific LDL binding,
internalization, and total uptake were computed by subtracting values
observed in the presence of 50-fold excess of unlabeled LDL from those
obtained in their absence. LDL degradation was measured from the ac-
cumulation ofnoniodide trichloroacetic acid-soluble '25I in the incubation
medium in excess of that occurring in the absence of cells (14). Each
experimental point represents the average value oftriplicate incubations.
In all experiments cells were preincubated for 24 h at 370C in a medium
containing 5% human LPDS to induce LDL receptors.
When appropriate the preincubation period was followed by incu-
bation for 2 h at 370C in a medium containing increasing amounts of
LPDS or IgA fraction obtained from control and from the patient serum.
Cells were then washed three times with PBS, 125I-LDL were added in a
fresh medium containing 5% of normal LPDS, and the incubation was
carried out either at 370C or 4VC for 5 h or 2 h, respectively. Binding,
internalization, and degradation of labeled LDL were determined as de-
scribed above. For experiments performed at 4VC, cells were placed for
30 min at 40C; the medium was then removed and replaced with a
chilled F-l 1 medium without bicarbonate and tricine supplemented with
10 mM Hepes (pH 7.4), 5% LPDS, penicillin, streptomycin, 1% non-
essential aminoacids, and the indicated concentration of '25I-LDL.
For competition experiments, cells were incubated with a fixed con-
centration of 1251I-LDL, (5 gg ofLDL protein) in the presence ofincreasing
concentrations of unlabeled LDL from control and patient serum.
To show specificity of the effect on the binding of LDL to their
cellular receptor, we studied the binding of '25I-HDL3 to human skin
fibroblasts. The experiments were performed as described by Biesborek
et al. (15) after incubation ofthe cells in an albumin containing medium
for 24 h. The binding of HDL was then evaluated as cell-associated
radioactivity because it has been shown that under these conditions no
appreciable internalization and degradation of HDL occur by human
skin fibroblasts (15).
Ligand-blotting experiments. Ligand-blotting analysis was performed
as described by Daniel et al. (16) using bovine adrenals as a source of
membranes rich in the LDL receptor (17). Membranes were prepared
as described (17) at 100,000 g and stored at -80'C as a pellet until use.
On the day of the experiment the pellet was thawed and solubilized in
1% Triton X-100 (final concentration). The soluble fraction was separated
from the particulate material by ultracentrifugation at 100,000 g for
1 h at 4°C and applied to a 5% acrylamide gel containing 0.1% sodium
dodecyl sulphate. Electrophoresis was run at 15 mA per plate for 6 h.
The separated proteins were then blotted to a nitrocellulose membrane
as described by Burnette (18) at 4°C at 250 mA for 6 h. Efficiency of
blotting was determined by staining of the gels; >85% ofthe protein was
blotted to the nitrocellulose. The cellulose was then incubated with buffer
A containing 3% albumin to quench the nonspecific binding sites. '25I-
LDL at a final concentration of 10 Ag protein/ml were then added to
buffer A and incubated at 27°C for 2-3 h. The incubation medium was
removed and the nitrocellulose sheet was washed at 4°C with the same
buffer containing no LDL (three washes, 30 min each).
In some experiments, after the incubation with albumin, the nitro-
Table I. Plasma Lipids and Cholesterol Distribution
among Lipoproteins in the Patient
Patient Controls§
mg/dl mg/dl
Plasma cholesterol* 600-900 190±18
Plasma triglyceride* 153-212 94±29
VLDL cholesterolt 40 17±11
LDL cholesterolt 538 123±14
HDL cholesterolt 40 48±6.6
Apo Bt 276 87±12
Apo A-It 121 139±17
* Range in four separate determinations.
t Plasma cholesterol was 640 mg/dl.
§ Values are the mean±SD of 20 normal subjects matched for sex and
age.
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Figure 1. Specific binding (o), internal-
ization (A), and degradation (o) of con-
trol '25l-LDL in vitro by cultured fibro-
blast from a normolipemic subject (left)
and patient F.F. (right). Increasing con-
centrations of 251I-LDL were incubated
with the cells for 5 h. The binding, in-
ternalization, and degradation were de-
....<, termined as described in Methods. Each
point is the mean of triplicate determi-
nations that did not differ by > 10%.
The nonspecific binding, internalization,
120 and degradation were the values ob-
tained in the presence of 500 Ag/ml ofunlabeled LDL.
cellulose was incubated for 2 h with LPDS (control or patient F.F.); final
concentration was 120 Ag protein/ml. The experiment was then per-
formed as outlined for the LDL.
To study the direct binding of patient IgA to the LDL receptor, the
immunoglobulin fraction was iodinated by the iodogen procedure (19)
to a specific activity of 1,500-1,900 cpm/ng. The experiments of ligand
blotting were performed as for the LDL. The dried nitrocellulose sheets
were then processed for autoradiography at -80'C using an intensifier
screen.
Results
Table I shows the plasma lipid levels and the cholesterol distri-
bution among lipoproteins in the patient. The phenotype was
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Ha. Family studies showed, however, that both parents were
normocholesterolemic (father 210 mg/dl; mother 190 mg/dl),
thus ruling out the possibility that we were dealing with a subject
affected by familial hypercholesterolemia. In fact, studies on
cultured skin fibroblasts obtained from patient F.F. showed that
the binding, internalization, and degradation ofLDL was normal
(Fig. 1). The LDL from the patient efficiently interacted with
the LDL receptor as shown in Fig. 2. The patient LDL were as
effective as control LDL in competing for '25I-LDL uptake, as
well as degradation (data not shown).
Fig. 3 shows the effect of control and patient F.F.'s LPDS
on the 251I-LDL degradation by human skin fibroblasts at 370C.
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Figure 2. Effect of control (m) and patient F.F.'s (-) LDL on the up-
take of '25I-LDL by cultured human skin fibroblasts. '251I-LDL
(5 ,ug/ml) were incubated for 5 h at 370C with the cells in presence of
the indicated amount of unlabeled LDL from a normolipemic subject
and from patient F.F. The nonspecific uptake was the LDL uptake in
the presence of 500 ,g/ml of control LDL. Each point is the mean of
triplicate determinations that did not differ by >10%.
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Figure 3. Effect of control (i) and patient F.F.'s (.) LPDS on the deg-
radation of '25I-LDL by cultured skin fibroblasts. Cells were preincu-
bated with the indicated amount of control LPDS for 2 h at 370C.
Protein concentration of control and patient F.F.'s LPDS was 20
mg/ml. The monolayer was washed thrice with PBS and then incu-
bated for 6 h with '25I-LDL (10 yg/ml) at 370C. LDL degradation was
determined as described in Methods. Each point is the mean of tripli-
cate determinations that did not differ by > 10%.
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Figure 4. Effect of patient F.F.'s LPDS before (.) and after (m) IgA im-
munoprecipitation on the binding of '25I-LDL. Cells were preincu-
bated with LPDS for 2 h at 37°C at the concentrations indicated in
the figure. Protein concentration of the LPDS was 20 mg/ml. The cells
were then washed thrice with PBS and the binding of '25I-LDL assayed
at 4°C as described in Methods. The nonspecific binding was the
125I-LDL bound in the presence of 500 ,ug/ml of unlabeled LDL. Each
point is the mean of triplicate determinations differing <10%.
Similar results were obtained for the binding at 4°C (data not
shown). LPDS from the patient clearly inhibited this process
while control LPDS did not.
Immunoprecipitation of IgA from the LPDS resulted in a
loss of the inhibitory activity (Fig. 4), suggesting that the IgA
was responsible for the LPDS effect. To directly address this
question, IgA were purified to homogeneity by affinity chro-
matography. This immunoglobulin was as effective as whole
LPDS in inhibiting 125I-LDL uptake and degradation whereas
control IgA had no effect (Fig. 5). It was therefore demonstrated
that in our patient the IgA fraction was responsible for the effects
ofLPDS upon the receptor-mediated catabolism of LDL.
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Although the tissue culture experiments were performed to
avoid any direct interaction in the medium between LDL and
LPDS or IgA, we also performed affinity-chromatography studies
to show that no interaction between LDL and the patient LPDS
components occurred. Indeed, these experiments showed that
none of the proteins present in the patient and control LPDS
interacted with LDL under the conditions used (Fig. 6) whereas
a rabbit antiserum to apo B contained a fraction that interacted
with LDL. To verify the specificity ofthe LPDS from the patient
in inhibiting the binding ofLDL, we studied its ability to interfere
with the binding ofapo E-free HDL3 to human skin fibroblasts.
The results in Table II show that neither control nor patient
F.F.'s LPDS affected the '25I-HDL binding.
Using the ligand-blotting technique, we then addressed the
question as to whether the IgA from our patient interacted di-
rectly with the LDL receptor. The patient's LPDS effectively
inhibited the binding of LDL to the receptor in this assay as
shown in Fig. 7 (lanes E and F), thus demonstrating a direct
effect on the receptor protein. Fig. 8 shows that 1251-labeled IgA
purified from patient F.F.'s serum directly interacted with a pro-
tein ofapproximately 160,000 mol wt (lanes A-C) with the same
mobility ofthe LDL receptor (lanes E and F). Treatment ofthe
membranes with reducing agents abolished the interaction of
patient F.F.'s IgA with the LDL receptor (lane D).
Discussion
Hypercholesterolemia (type Ha) is a risk factor for coronary heart
disease (1). Genetic forms of this disease relate to the deficiency
(partial or total) ofLDL receptors; hypercholesterolemic subjects
exist, however, that are nonfamilial and therefore no loss of
receptor activity occurs (1).
Autoantibodies to lipoprotein receptors have not been pre-
viously recognized as "secondary" causes of hypercholestero-
lemia. However, autoantibodies to other receptors (insulin, ace-
tylcholine, and thyrotropin) have been described (20-22), which
lead to severe forms ofdiabetes, myasthenia gravis, and Graves'
syndrome. Autoantibodies to lipoprotein components as well as
to lipolytic enzymes have also been reported (4-8), and these
conditions are related to hyperlipemia with increased plasma
concentrations of triglycerides and cholesterol.
We report here on a patient whose LPDS contains an anti-
body-like protein that inhibits the receptor-mediated binding
Figure 5. Effect of control (n) and patient F.F.'s (.) IgA
on the uptake and degradation of '25I-LDL by cultured
= ~* skin fibroblasts. Cells were preincubated with IgA as de-
scribed in the legends to Figs. 3 and 4 and then incu-
bated for 5 h at 37°C in presence of 10 ;g/mI of 25I-
LDL. The nonspecific uptake was the uptake in the
75 presence of 500 jg/ml unlabeled LDL. Each point is the
mean of triplicate determinations that did not differ by
IgA /ug/ml > 10%.
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and catabolism ofLDL by human skin fibroblasts in vitro. The
experiments performed after immunoprecipitation of IgA
strongly suggest that this factor is an antibody (see Fig. 4), and
the data obtained using purified IgA indeed show that the activity
is completely attributable to this globulin fraction (Fig. 5).
It is known that monoclonal antibodies to Apo B may inhibit
LDL catabolism (23, 24). The lipoprotein profile ofour patient,
however, differs from that of subjects whose serum contains au-
toantibodies against LDL. These patients have, in fact, also in-
creased plasma triglyceride levels and most of the antibody can
be found at the d < 1.21 g/ml top (5, 8) associated with lipo-
proteins. Our patient was normotriglyceridemic, his LDL were
normal both in chemical composition and ability to interact
with cellular receptors, and the inhibiting activity was not as-
sociated with lipoproteins. Along this line we have also shown
that this antibody does not bind to LDL (see Fig. 6); these data,
however, must be regarded with caution, for under the experi-
mental conditions used, an antibody may fail to interact with
LDL or may not be released from the column. Nevertheless,
these data further support the tissue culture experiments in vitro
which were designed to avoid any direct interaction between
LPDS or IgA and LDL in the medium.
The antibody might therefore act by directly binding the
receptor or interacting with the cell membrane near the LDL
receptor producing steric hindrance of the LDL-receptor inter-
action. Alternatively, the antibody might interact with a mem-
Table II. Effect ofLPDS on the Binding
ofApo E-free HDL3 to Fibroblasts *
'25I-HDL3 bound
LPDS F.F. Control
jtz/mi ng ng
- 69.9 69.9
20 63.2 70.1
50 69.0 60.2
150 61.4 72.9
* Data are expressed as nanograms of '25I-HDL protein bound per
milligram of cell protein. Cells were preincubated with a medium con-
taining albumin for 24 h and the binding determined at 370C as de-
scribed in Methods. The data are means of triplicate determinations
that did not differ by >10%.
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Figure 6. Elution profile of a LDL-Sepharose column.
Patient F.F. LPDS (A), control LPDS (B), and a rabbit
polyclonal anti-human apo B serum (C) were applied
to the column. Only the fractions eluted with I M gly-
cine, pH 2.5, are presented.
brane component distant from the receptor, modulating the
LDL-receptor interaction. To study the specificity of this anti-
body, we investigated whether it could also affect the binding of
HDL3 to human skin fibroblasts (see Table II). Binding sites for
HDL are present on a number of tissues and are distinct in
terms of specificity and regulation from the LDL receptor. (15,
25, 26). No interference with the binding of HDL was found
suggesting that the effect ofthe antibody is specific, at least among
the lipoproteins, for the LDL receptor. Finally, the ligand-blotting
experiments demonstrate that IgA from the patient interact in
vitro with the LDL receptor and that treatment ofthe membrane
proteins with reducing agents destroys the epitope recognized
by the antibody, suggesting that the area ofthe receptor involved
in the LDL binding contains the epitope(s) recognized by the
antibody. A loss of the receptor secondary structure abolishes
the binding ofLDL as well as of the antibody. Interestingly, the
epitope for a mouse monoclonal antibody was also not retained
after exposure of the LDL receptor to reducing agents (16).
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Figure 7. Effect of patient F.F.'s LPDS on the binding of 1251-LDL to
the LDL receptor from bovine adrenal cortexes. For the ligand-blot-
ting assay, membranes were solubilized with Triton X-100 (1% vol/
vol) and run on a 5% sodium dodecyl sulfate-acrylamide gel, blotted
to a nitrocellulose filter. 25 jsg (lanes A, C, and E) or 50 ,g (lanes B,
D, and F) of membrane protein were applied to the gels. The lanes
were cut and incubated at 27°C for 2 h with control LPDS (120
jig/ml, lanes A and B) or patient F.F.'s LPDS (120 jtg/ml, lanes E and
F). The sheets were washed and incubated at 27°C for 2 h with 12511
LDL (10 Mg/ml) without unlabeled LDL (lanes A, B, E, and F) or
with 0.5 mg/ml unlabeled LDL (lanes C and D). The high molecular
weight components in lane B may represent aggregated receptor pro-
tein.
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Figure 8. Binding of"25I-labeled IgA isolated from patient F.F.'s LPDS
to the LDL receptor. IgA were labeledwith 1251 as described in Meth-
ods. 5, 10, 15, and 10 Ag of membrane protein (lanes A-D) were ap-
plied to the sodium dodecyl sulfate acrylamide gels and were blotted
to nitrocellulose. The binding was performed in PBS containing 2%
bovine serum albumin for 2 h at 270C. The sample in lane D was pre-
treated with 5% fl-mercaptoethanol. For comparative purposes the
binding of25I-LDL is shown (lanes E and F,10 and 15 Mg of mem-
brane protein applied). The area of higher moleculer weight in lanes
A, B, and C may represent aggregated receptor protein.
The degree of hypercholesterolemia in our patient is com-
parable to that ofhomozygotes for familial hypercholesterolemia,
although at the most the antibody reduces LDL binding to the
receptor by 70%. Patients receptor-defective also have severe
hypercholesterolemia even though 15-20% of the receptor ac-
tivity is present (1).
The causal relation between antibodies and hypercholester-
olemia in our patient, although likely, is not demonstrated. Bei-
siegel et al. (27) and Kita et al. (28) reported that antibodies to
the LDL receptor interfere with LDL catabolism in vitro as well
as in vivo. In this respect our patient will be very similar to
patients with severe insulin resistance, Graves' disease, or myas-
thenia gravis who have autoantibodies to the insulin, acetylcho-
line, and thyrotropin receptors, respectively (20-22). These an-
tibodies have a number of physiologic effects and some also
mimic the effect of the physiological ligand (29). The question
as to whether binding of the autoantibody to the LDL receptor
in our patient leads to the receptor internalization and down-
regulation as it occurs for LDL (1, 2) remains to be addressed.
Finally, this autoantibody recognized also the LDL receptor
present on bovine adrenal cortexes. A mouse monoclonal an-
tibody against the bovine receptor cross-reacts with the human,
bovine, and dog LDL receptor (27) but does not recognize the
rabbit receptor. We are currently addressing the question as to
whether patient F.F.'s IgA has a broad interspecies specificity.
In summary, we have described in the plasma of a hyper-
cholesterolemic patient the presence of autoantibodies to the
LDL receptor that inhibit the in vitro catabolism of LDL. The
clinical history ofthe patient is similar to that ofthe homozygous
and heterozygous forms of hypercholesterolemia. Screening
among the nonfamilial forms of moderate and severe hyper-
cholesterolemia may result in the discovery of other patients.
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